---
title: "Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295429730.md"
description: "Scholar Rock announced that the FDA review for its SMA treatment apitegromab will proceed exclusively using a secondary U.S. manufacturing facility, keeping the September 30 PDUFA approval date on schedule. The company withdrew the Catalent Indiana site following an FDA Official Action Indicated classification. A robust inventory from the alternative site is ready for commercial packaging upon approval."
datetime: "2026-08-10T16:03:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295429730.md)
  - [en](https://longbridge.com/en/news/295429730.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295429730.md)
generator: "portal-rs"
---

# Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule

On Friday, **Scholar Rock** **Holding Corporation** (NASDAQ:SRRK), a biopharmaceutical firm utilizing myostatin biology for neuromuscular conditions, announced that the Food and Drug Administration (FDA) review of its Biologics License Application (BLA) for apitegromab is moving forward exclusively with its secondary fill-finish facility.

The company seeks approval for the drug for children and adults with spinal muscular atrophy (SMA).

Despite the manufacturing pivot, the Prescription Drug User Fee Act (PDUFA) action date remains firmly on track for September 30.

In its original March 2026 application, the company strategically included two manufacturing sites to establish independent pathways for regulatory clearance.

 **Read Also: FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults** 

However, on Friday, Catalent Indiana LLC—a facility associated with **Novo Nordisk A/S** (NYSE:NVO)—notified the company that the FDA had issued an Official Action Indicated (OAI) classification following an April 2026 site inspection.

Working under the guidance of the FDA, the company decided to withdraw the Catalent location from its submission. The agency’s evaluation will now proceed solely relying on the alternative U.S.-based site.

## Regulatory Progress And Supply Readiness

During a prior meeting in March 2026, both parties agreed on the specific data requirements for the alternative manufacturing plant.

The alternative plant currently manufactures multiple commercial products and maintains a solid standing with both the FDA and the European Medicines Agency (EMA).

A robust inventory from this location is already available and waiting at a third-party provider for final commercial packaging upon regulatory approval.

## European Regulatory Updates

Overseas, the company continues its dialogue with the EMA regarding the integration of this secondary manufacturing site into the European Marketing Authorization Application.

A revised schedule for the Committee for Medicinal Products for Human Use opinion will be provided once alignment with European regulators is finalized.

**SRRK Price Action:** Scholar Rock Holding shares were down 3.14% at $51.26 at the time of publication on Monday, according to Benzinga Pro data.

 **Read Also: ‘Moneymaxxing’ Is Making Frugality Cool Again as Younger Americans Struggle To Get Ahead** 

*Image via Shutterstock*

### Related Stocks

- [SRRK.US](https://longbridge.com/en/quote/SRRK.US.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

- [Scholar Rock withdraws Europe filing for muscle weakness drug, plans resubmission](https://longbridge.com/en/news/296631683.md)
- [Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan | SRRK Stock News](https://longbridge.com/en/news/296622602.md)
- [Teva Pharmaceutical Industries (TEVA) Could Be 10% Undervalued After FDA Accepted Ecopipam NDA](https://longbridge.com/en/news/296924113.md)
- [Endovia Health opens FDA INAD file for CannEpil veterinary program](https://longbridge.com/en/news/296915045.md)
- [Does First-in-Class FOP Drug Approval Transform the Bull Case For Regeneron Pharmaceuticals (REGN)?](https://longbridge.com/en/news/296702017.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**